India Pharma Outlook Team | Monday, 29 January 2024
The UK Medicines and Healthcare Products Regulatory Agency (MHRA) have approved the diabetes and weight management drug Mounjaro (tripeptide), a four-part version (with one month of treatment) of the Mounjaro KwikPen.
Mounjaro KwikPen is approved for treating type 2 diabetes in adults and weight control in elderly patients with a BMI of 30 kg/m² or more (obese) and in elderly patients with a BMI of 27 to 30 kg/m² (very heavy ).
A weight-related health problem, such as prediabetes, high blood pressure, high cholesterol, or heart problems. This medication should be used with a low-calorie diet and increased physical activity. Julian Beach, director of care quality and access at the MHRA, said:
"The public health importance of safe and effective treatments to help manage diabetes and high disease can have a significant impact on human health." This approval will improve. Use of the approved Mounjaro pen for treatment once a week for a month.
"Douglas Twenefour, head of Diabetes Care UK, said: "We hope that the MHRA's approval of this device will help people with type 2 diabetes accesses this effective treatment.
"Helping people with type 2 diabetes lose weight and control their blood sugar is essential to reduce the risk of diabetes-related complications, and Mounjaro offers the kinds of treatment to help people cope with this. Increase it.
"Mounjaro KwikPen is available as a four-part pre-filled pen containing 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg of tripeptide per dose administered intra-abdominally to the patient, in the thigh or under the skin.
It will be injected. The starting dose is 2.5 mg once weekly for four weeks, increasing to 5 mg weekly. If the patient's doctor recommends, the dose can be increased to 15 mg (once a week) at 4-week intervals.
.jpg)
